These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1123 related articles for article (PubMed ID: 10604725)
1. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF; Koberle B; Masters JR; Kelland LR Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. Mellish KJ; Kelland LR Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466 [TBL] [Abstract][Full Text] [Related]
3. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Sharp SY; Rogers PM; Kelland LR Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070 [TBL] [Abstract][Full Text] [Related]
4. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261 [TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318 [TBL] [Abstract][Full Text] [Related]
7. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660 [TBL] [Abstract][Full Text] [Related]
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
9. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093 [TBL] [Abstract][Full Text] [Related]
10. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719 [TBL] [Abstract][Full Text] [Related]
11. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278 [TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF; Hunakova L; Kelland LR Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899 [TBL] [Abstract][Full Text] [Related]
13. Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro. Drewa T; Olszewska-Słonina D; Woźniak A; Styczyński J; Drewa G; Szłyk E; Lakomska I; Kobe J; Czajkowski R Acta Pol Pharm; 2004; 61(1):39-44. PubMed ID: 15259856 [TBL] [Abstract][Full Text] [Related]
14. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901 [TBL] [Abstract][Full Text] [Related]
15. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870 [TBL] [Abstract][Full Text] [Related]
16. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362 [TBL] [Abstract][Full Text] [Related]
17. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Reardon JT; Vaisman A; Chaney SG; Sancar A Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593 [TBL] [Abstract][Full Text] [Related]
18. Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. Hess SM; Mounce AM; Sequeira RC; Augustus TM; Ackley MC; Bierbach U Cancer Chemother Pharmacol; 2005 Oct; 56(4):337-43. PubMed ID: 15895232 [TBL] [Abstract][Full Text] [Related]
19. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229 [TBL] [Abstract][Full Text] [Related]
20. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]